| Literature DB >> 35689652 |
Charis Xuan Xie1, Qiuzhe Chen2,3, Cesar A Hincapié4,5, Léonie Hofstetter4, Chris G Maher2,3, Gustavo C Machado2,3.
Abstract
BACKGROUND: Clinical dashboards used as audit and feedback (A&F) or clinical decision support systems (CDSS) are increasingly adopted in healthcare. However, their effectiveness in changing the behavior of clinicians or patients is still unclear. This systematic review aims to investigate the effectiveness of clinical dashboards used as CDSS or A&F tools (as a standalone intervention or part of a multifaceted intervention) in primary care or hospital settings on medication prescription/adherence and test ordering.Entities:
Keywords: audit and feedback; clinical decision support; dashboard; review
Mesh:
Substances:
Year: 2022 PMID: 35689652 PMCID: PMC9471705 DOI: 10.1093/jamia/ocac094
Source DB: PubMed Journal: J Am Med Inform Assoc ISSN: 1067-5027 Impact factor: 7.942
Figure 1.PRISMA flow diagram. The PRIMSA flow diagram presents the systematic search and selection process in this review, detailing the number of records included and excluded at different stages and showing the final number of included studies.
Characteristics of the included studies
| Study | Design | Setting | Dashboard types | Dashboard features | Outcomes |
|---|---|---|---|---|---|
|
Linder et al USA | Cluster randomized controlled trial | 27 primary care practices |
Quality dashboard displaying antibiotic prescribing and billing practices data for acute respiratory infections |
Bar graph displayed clinician’s prescribing rates for acute respiratory infections for previous year (data updated monthly) vs clinic peers and national benchmarks. Dashboard allowed clinicians to “drill down” to view any individual patient medical record. |
Primary: antibiotic prescribing rate for all acute respiratory infection visits. Secondary: antibiotic prescribing rate for: (1) antibiotic-appropriate acute respiratory infection visits and (2) non–antibiotic-appropriate acute respiratory infection visits. |
|
Patel et al USA | Cluster randomized controlled trial | 32 primary care clinics at the University of Pennsylvania Health System |
An automated patient dashboard listing patients who met national guidelines for statin therapy but had not been prescribed this medication. |
Dashboard linked to the American College of Cardiology/American Heart Association guidelines, showed options for selecting statin dosage. Dashboard provided clinicians a list of patients who met guidelines for statin therapy but have not been prescribed, to be reviewed in 1 wk. Also provided clinician performance feedback based on baseline statin prescribing rates and compared with peers. Data were obtained from patient electronic health records. | Primary: statin prescribing rates for atherosclerotic cardiovascular disease in dashboard only group and dashboard with peer comparison group. |
|
EI Miedany et al Europe | Randomized controlled trial | Not reported |
A visual feedback tool in the management of rheumatology |
Dashboard enabled patients to monitor real-time changes of their disease activity parameters and patient’s reported outcome measures. Electronic data recording in the standard rheumatology clinical practices were integrated in the visual feedback system. | Primary: the change in the patients’ adherence to medications. |
|
Ryskina et al USA | Cluster randomized controlled trial | Hospital of the University of Pennsylvania |
A personalized, EMR-based, real-time dashboard containing patient level details for internal medicine residents |
Dashboard provided the internal medicine residents with feedback on their use of routine laboratory tests relative to service averages. Dashboard contained real-time lab ordering information which was linked to individual patients’ EMR records. | Primary outcome: the count of routine laboratory test orders placed by a physician per patient-day. |
|
Coombs et al Australia | Stepped-wedge, cluster-randomized trial | 4 EDs in New South Wales, Australia |
Real-time dashboard developed in Qlik Sense for clinicians |
Dashboard provided clinicians with structured real-time audit and feedback data on department-level imaging, opioid and inpatient admission rates. Dashboard was integrated into the electronic medical record system. |
Primary outcome: the proportion of low back pain presentations receiving lumbar imaging. Secondary outcomes: healthcare utilization outcomes included prescriptions of pain medicines. |
|
Chang et al China | Cluster randomized crossover open controlled trial | 31 township public hospitals |
A computer network-based feedback dashboard for physicians |
Dashboard displayed physicians’ antibiotic prescription rates, frequency and ranking updated every 10 d. Dashboard presented top 5 diseases of patients, number of prescriptions, antibiotic frequency and prescription rate, precautions and contraindications for antibiotics being use. Enabled pop-up window to automatically prompt physicians to check for the feedback information every 10 d. | Primary outcome: 10-d antibiotic prescription rate of physicians (defined as the number of antibiotic prescriptions divided by the total number of the prescriptions in each 10-d time period). |
|
Du et al USA | Randomized controlled trial | A telemedicine practice |
Individualized prescribing feedback dashboards for clinicians |
Dashboard displayed monthly rates of personal and practice-wide antibiotic prescription rates starting May 2018 and summarized antibiotic prescription rates for the previous month. Data were collected from patient electronic health records. | Primary outcome: antibiotic prescription rates for each of the 4 diagnostic categories: upper respiratory infection, bronchitis, sinusitis, and pharyngitis. |
|
Jung et al South Korea | Randomized controlled trial | A university hospital |
ICT-based centralized monitoring dashboard for increasing medication adherence among kidney transplant recipients | The ICT based centralized monitoring system alerted both patients and medical staff with texts and pill box alarms. | Primary outcome: medical adherence among kidney transplant recipients. |
|
Peiris et al Australia | Cluster Randomized Trial | 60 primary healthcare centers |
Cardiovascular disease risk management dashboard |
Dashboard allowed health services to audit health records, identify performance gaps, and establish recall/reminder prompts rapidly. Dashboard used traffic light prompts to alert the practitioner to suggest recommendations. |
Primary outcomes: (1) the proportion of eligible patients who received appropriate screening of CVD risk factors and (2) the proportion of eligible patients defined at baseline as being at high CVD risk receiving recommended medication prescriptions at the end of study. Secondary outcomes (1) escalation of drug prescription among patients at high CVD risk (either newly prescribed or additional numbers of antiplatelet, BP-lowering, and lipid-lowering agents). |
|
Hemkens et al Switzerland | Randomized controlled trial | National-wide primary care practices |
Personalized prescription feedback dashboard for physicians | Dashboard displayed of quarterly updated single-page graphical overview (bar chart) showing individual amount of antibiotic prescriptions per 100 consultations in the preceding months and the adjusted average in peer physicians across national-wide physician population. | Primary outcome: the prescribed defined daily doses (DDD) of any type of antibiotics to any patient per 100 consultations in the first and second year. |
|
Elouafkaoui et al UK | Cluster Randomized Trial | 795 antibiotic prescribing NHS general dental practices in Scotland |
A graphical individualized audit and feedback dashboard for dentists |
Dashboard displayed line graph plotting the individual dentist’s monthly antibiotic prescribing rate. Data were derived from 2 routinely collected electronic healthcare datasets held centrally by the Information Services Division of NHS National Services Scotland. |
Primary outcome: the total number of antibiotic items dispensed per 100 NHS treatment claims over 12 mo. Secondary outcomes: (1) the defined daily dose (DDD) prescribing rates over 12 mo, (2) the total number of amoxicillin 3g dispensed per 100 NHS treatment claims over 12 mo, and (3) the total number of broad-spectrum antibiotics dispensed per 100 NHS treatment claims over 12 mo. |
Figure 2.The risk of bias for individual trials. D1: Bias arising from the randomization process. D1a (for cluster-randomized designs): Bias arising from the randomization process. D1b (for cluster-randomized designs): Bias arising from the timing of identification or recruitment of participants. D2: Bias due to deviations from intended intervention. D3: Bias due to missing outcome data. D4: Bias in measurement of the outcome. D5: Bias in selection of the reported result. (X) high risk of bias; (−) some concerns; (+) low risk of bias.
Summary of findings
| Study | Time frame | Outcomes | |||
|---|---|---|---|---|---|
| Trial groups Intervention (I) Control (C) | Medication prescription/adherence | Test ordering | Quality of the evidence (GRADE) | ||
| Computerized feedback dashboard compared with usual care/no intervention ( | |||||
|
Linder et al USA | 9-mo intervention period |
I: 14 primary care practices (258 clinicians, 8406 visits for acute respiratory infection) C: 13 primary care practices (315 clinicians, 10 082 visits for acute respiratory infection) |
Antibiotic prescribing rate for all acute respiratory infection visits: OR = 0.97; 95% CI = 0.70–1.40 Antibiotic prescribing rate for antibiotic-appropriate acute respiratory infection visits: I : 63% vs C: 68%; OR = 0.78; 95% CI = 0.53–1.15 Antibiotic prescribing rate for non–antibiotic-appropriate acute respiratory infection visits: I: 32% vs C: 43%; OR = 0.63; 95% CI = 0.45, 0.86 | Not reported | Moderate |
|
Patel et al USA | 2-mo intervention period |
I (dashboard): 32 physicians and 1743 patients with atherosclerotic cardiovascular disease (ASCVD) I (dashboard with peer comparison): 32 physicians and 1465 patients with ASCVD C: 32 physicians and 1566 patients with ASCVD |
Statin prescribing rate for atherosclerotic cardiovascular disease: Dashboard only vs usual care: adjusted difference in percentage points, 4.1; 95% CI = −0.8 to 13.1 Dashboard with peer comparison vs usual care: adjusted difference in percentage points, 5.8; 95% CI, 0.9–13.5 | Not reported | High |
|
EI Miedany et al Europe |
6-mo intervention period; (outcome measured over 12 mo) |
I: 55 patients diagnosed with early inflammatory arthritis and receiving disease-modifying antirheumatic drug therapy C: 56 patients diagnosed with early inflammatory arthritis and receiving disease-modifying antirheumatic drugs therapy | Medication adherence for disease-modifying antirheumatic drug therapy: I: 87% of patients vs. C: 43% of patients, | Not reported | Low |
|
Ryskina et al USA | 6-mo intervention period |
I: 39 medicine interns and residents C: 34 medicine interns and residents 41 in crossover group: 19 control first then intervention; 22 intervention first then control (114 participants in total) | Count of routine laboratory test orders: −0.14; 95% CI −0.56 to 0.27 | Moderate | |
|
Chang et al China | 6-mo intervention period |
Group 1 (received intervention first then control): 82 primary care physicians Group 2 (received control first then intervention): 81 primary care physicians | 10-d antibiotic prescription rate: coef. −0.04, 95% CI −0.07 to −0.01 | Not reported | Very low |
|
Jung et al South Korea | 24-wk intervention period |
I: 57 kidney transplant recipients C: 57 kidney transplant recipients | Medical adherence among kidney transplant recipients: no significant between-group difference (no point estimates and 95% CI reported) | Not reported | Very low |
|
Hemkens et al Switzerland | 2-y follow-up |
I: 1450 primary care physicians C: 1450 primary care physicians |
Defined daily doses (DDD) of antibiotic items to any patient per 100 consultations: First year: 0.81%; 95% CI, −2.56% to 4.30% Second year: −1.73%; 95% CI, −5.07% to 1.72% | Not reported | High |
|
Elouafkaoui et al UK | 12-mo intervention period |
I: 632 general dental practices (1999 dentists) C: 163 general dental practices (567 dentists) |
Number of antibiotic items dispensed per 100 NHS treatment claims: −5.7%; 95% CI −10.2% to −1.1% Defined daily dose (DDD) prescribing rates per 100 NHS treatment claims: −6.6%; 95% CI −12.5% to −0.7% Number of amoxicillin 3g dispensed per 100 NHS treatment claims: −26.0%; 95% CI −64.9% to 13.0% Number of broad-spectrum antibiotics dispensed per 100 NHS treatment claims: −33.3%; 95% CI −80.0% to 20.0% | Not reported | Moderate |
| Multifaceted interventions incorporating a dashboard component compared with usual care/no intervention ( | |||||
|
Coombs et al Australia | 4-mo intervention period |
I: 4 emergency departments (1392 episodes of care for low back pain) C: 4 emergency departments (3233 episodes of care for low back pain) |
Opioid administration rate: OR 0.57; 95% CI 0.38–0.85 Strong opioids administration rate: OR 0.69, 95% CI 0.46–1.04 Nonopioid pain medicines administration rate: OR 1.52, 95% CI 0.98–2.3 | Lumbar imaging referral rate: OR 0.77; 95% CI 0.47–1.26 | High |
|
Peiris et al Australia |
Median follow-up for intervention and control arms was 17.3 and 17.7 mo |
I: 30 general practice services (19 385 patients at high CVD risk) C: 30 general practice services (19 340 patients at high CVD risk) | Appropriate medication prescription rate: RR 1.11; 95% CI, 0.97–1.27
antiplatelet medications: RR 4.80; 95% CI 2.47–9.29 lipid-lowering medications: RR 3.22; 95% CI 1.77–5.88 blood pressure-lowering medications: RR 1.89; 95% CI, 1.08–3.28 | Appropriate CVD risk screening rate: RR 1.25; 95% CI 1.04–1.50 | Moderate |
| Multifaceted interventions incorporating a dashboard component compared with similar system without dashboard component ( | |||||
|
Du et al USA | 11-mo intervention period |
I: 22 primary care clinicians C: 23 primary care clinicians |
Antibiotic prescription rates for: Upper respiratory infection: ITR 0.60, 95% CI 0.47–0.77 Bronchitis: ITR 0.42, 95% CI 0.32–0.55 Sinusitis: ITR 1.05, 95% CI 0.91–1.21 Pharyngitis: ITR 0.91, 95% CI 0.76–1.09 | Not reported | Moderate |